Progress in Cardiovascular Diseases
Volume 46, Issue 1 , Pages 91-111 , July 2003

Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment

  • Neal L Benowitz

      Affiliations

    • Corresponding Author InformationReprint requests: Neal L. Benowitz, MD, Clinical Pharmacology and Experimental Therapeutics, University of California San Francisco, San Francisco General Hospital, Box 1220, San Francisco, CA 94143-1220, USA
    • Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, USA

References 

  1. Burns DM. Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis. 2003;46:11–29
  2. Moller AM, Villebro N, Pedersen T, et al.  Effect of preoperative smoking intervention on postoperative complications (a randomised clinical trial). Lancet. 2002;359:114–117
  3. Voors AA, van Brussel BL, Plokker HW, et al.  Smoking and cardiac events after venous coronary bypass surgery (a 15-year follow-up study). Circulation. 1996;93:42–47
  4. Daly LE, Mulcahy R, Graham IM, et al.  Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. Br Med J. 1983;287:324–326
  5. Metz L, Waters DD. Implications of cigarette smoking for the management of patients with acute coronary syndromes. Prog Cardiovasc Dis. 2003;46:1–10
  6. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis. 2003;46:31–38
  7. Knight-Lozano CA, Young CG, Burow DL, et al.  Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002;105:849–854
  8. Valkonen M, Kuusi T. Passive smoking induces atherogenic changes in low-density lipoprotein. Circulation. 1998;97:2012–2016
  9. Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation. 1991;82:1–12
  10. Asplund K. Smokeless tobacco and cardiovascular disease. Prog Cardiovasc Dis. 2003;45:383–394
  11. Wennmalm A, Benthin G, Granström EF, et al.  Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation. 1991;83:1698–1704
  12. Benowitz NL, Porchet H, Sheiner L, et al.  Nicotine absorption and cardiovascular effects with smokeless tobacco use (comparison with cigarettes and nicotine gum). Clin Pharmacol Ther. 1988;44:23–28
  13. Porchet HC, Benowitz NL, Sheiner LB, et al.  Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics. J Clin Invest. 1987;80:1466–1471
  14. Benowitz NL, Jacob P, Yu L. Daily use of smokeless tobacco (Systemic effects). Ann Int Med. 1989;111:112–116
  15. Green MS, Jucha E, Luz Y. Blood pressure in smokers and nonsmokers (epidemiologic findings). Am Heart J. 1986;111:932–940
  16. Persson PG, Carlsson S, Svanstrom L, et al.  Cigarette smoking, oral moist snuff use, and glucose intolerance. J Intern Med. 2000;248:103–110
  17. Henningfield JE, Stapleton JM, Benowitz NL, et al.  Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23–29
  18. Benowitz NL, Kuyt F, Jacob P. Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther. 1982;32:758–764
  19. Benowitz NL, Jacob P, Denaro C, et al.  Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther. 1991;49:270–277
  20. Porchet HC, Benowitz NL, Sheiner LB. Pharmacodynamic model of tolerance (Application to nicotine). J Pharmacol Exp Ther. 1988;244:231–236
  21. Benowitz NL, Jacob P, Jones RT, et al.  Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther. 1982;221:368–372
  22. Benowitz NL, Kuyt F, Jacob P. Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking. Clin Pharmacol Ther. 1984;36:74–81
  23. Allred EN, Bleecker ER, Chaitman BR, et al.  Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease. N Engl J Med. 1989;321:1426–1432 [published erratum appears in N Engl J Med 1990;322:1019, see comments]
  24. Calverley PMA, Leggett RJE, Flenley DC. Carbon monoxide and exercise tolerance in chronic bronchitis and emphysema. Br Med J. 1981;283:878–880
  25. Sheps DS, Herbst MC, Hinderliter AL, et al.  Production of arrhythmias by elevated carboxyhemoglobin in patients with coronary artery disease. Ann Int Med. 1990;113:343–351
  26. DeBias DA, Banerjee CM, Birkhead NC, et al.  Effects of carbon monoxide inhalation on ventricular fibrillation. Arch Environ Health. 1976;31:38–42
  27. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect. 1985;64:111–126
  28. Lykkesfeldt J, Christen S, Wallock LM, et al.  Ascorbate is depleted by smoking and repleted by moderate supplementation (a study in male smokers and nonsmokers with matched dietary antioxidant intakes). Am J Clin Nutr. 2000;71:530–536
  29. Morrow JD, Frei B, Longmire AW, et al.  Increase in circulating products of lipid peroxidation (F2 - isoprostanes) in smokers. N Engl J Med. 1995;332:1198–1203
  30. Burke A, FitzGerald GA. Oxidative stress and smoking-induced tissue injury. Prog Cardiovasc Dis. 2003;46:79–90
  31. Penn A, Snyder C. Arteriosclerotic plaque development is ‘promoted’ by polynuclear aromatic hydrocarbons. Carcinogenesis. 1988;9:2185–2189
  32. Penn A, Snyder CA. 1,3 Butadiene, a vapor phase component of environmental tobacco smoke, accelerates arteriosclerotic plaque development. Circulation. 1996;93:552–557
  33. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine (implications for nicotine replacement therapy). J Am Coll Card. 1997;29:1422–1431
  34. Czernin J, Waldherr C. Cigarette smoking and coronary blood flow. Prog Cardiovasc Dis. 2003;45:395–404
  35. Woodman OL. Coronary vascular responses to nicotine in the anaesthetized dog. Naunyn Schmiedebergs Arch Pharmacol. 1991;343:65–69
  36. Puranik R, Celermajer DS. Smoking and endothelial function. Prog Cardiovasc Dis. 2003;45:443–458
  37. Kharitonov SA, Robbins RA, Yates D, et al.  Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med. 1995;152:609–612
  38. Robbins RA, Millatmal T, Lassi K, et al.  Smoking cessation is associated with an increase in exhaled nitric oxide. Chest. 1997;112:313–318
  39. Nicod P, Rehr R, Winniford MD, et al.  Acute systemic and coronary hemodynamic and serologic responses to cigarette smoking in long-term smokers with atherosclerotic coronary artery disease. J Am Coll Cardiol. 1984;4:964–971
  40. Winniford MD, Wheelan KR, Kremers MS, et al.  Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease (evidence for adrenergically mediated alterations in coronary artery tone). Circulation. 1986;73:662–667
  41. Quillen JE, Rossen JD, Oskarsson HJ, et al.  Acute effect of cigarette smoking on the coronary circulation (constriction of epicardial and resistance vessels). J Am Coll Cardiol. 1993;22:642–647
  42. Winniford MD, Jansen DE, Reynolds GA, et al.  Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol. 1987;59:203–207
  43. Kaijser L, Berglund B. Effect of nicotine on coronary blood-flow in man. Clin Physiol. 1985;5:541–552
  44. Przyklenk K. Nicotine exacerbates postischemic contractile dysfunction of stunned myocardium in the canine model (possible role of free radicals). Circulation. 1994;89:1272–1281
  45. Caralis DG, Ubeydullah D, Kern MJ, et al.  Smoking is a risk factor for coronary spasm in young women. Circulation. 1992;85:905–909
  46. Maouad J, Fernandez F, Hebert JL, et al.  Cigarette smoking during coronary angiography (diffuse or focal narrowing (spasm) of the coronary arteries in 13 patients with angina at rest and nromal coronary angiograms). Cathet Cardiovasc Diagn. 1986;12:366–375
  47. Asmussen I, Kjeldsen K. Intimal ultrastructure of human umbilical arteries. Observations on arteries from newborn children of smoking and nonsmoking mothers. Circ Res. 1975;36:579–589
  48. Celermajer DS, Sorensen KE, Georgakopoulos D, et al.  Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149–2155
  49. Nitenberg A, Antony I, Foult J-M. Acetylcholine-induced coronary vasoconstriction in young, heavy smokers with normal coronary arteriographic findings. Am J Med. 1993;95:71–77
  50. Heitzer T, Yla-Herttuala S, Luoma J, et al.  Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation. 1996;93:1346–1353
  51. Heitzer T, Just H, Munzell T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 1996;94:6–9
  52. Csonka E, Somogyi A, Augustin J, et al.  The effect of nicotine on cultured cells of vascular origin. Virchows Archiv A Pathological Anatomy and Histology. 1985;407:441–447
  53. Thyberg J. Effects of nicotine on phenotypic modulation and initiation of DNA synthesis in cultured arterial smooth muscle cells. Virchows Archiv. 1986;52:25–32
  54. Krupski WC, Olive GC, Weber CA, et al.  Comparative effects of hypertension and nicotine on injury-induced myointimal thickening. Surgery. 1987;102:409–415
  55. Davis JW, Shelton L, Eigenberg DA, et al.  Effects of tobacco and non-tobacco cigarette smoking on endothelium and platelets. Clin Pharmacol Ther. 1985;37:529–533
  56. Mayhan WG, Patel KP. Effect of nicotine on endothelium-dependent arteriolar dilatation in vivo. Am J Physiol. 1997;272:H2337–2342
  57. Chalon S, Moreno H, Benowitz NL, et al.  Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther. 2000;67:391–397
  58. Sarabi M, Lind L. Short-term effects of smoking and nicotine chewing gum on endothelium-dependent vasodilation in young healthy habitual smokers. J Cardiovasc Pharmacol. 2000;35:451–456
  59. Neunteufl T, Heher S, Kostner K, et al.  Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J Am Coll Cardiol. 2002;39:251–256
  60. Cucina A, Corvino V, Sapienza P, et al.  Nicotine regulates basic fibroblastic growth factor and transforming growth factor β1 production in endothelial cells. Biochem Biophys Res Commun. 1999;257:306–312
  61. Villablanca AC. Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro. J Appl Physiol. 1998;84:2089–2098
  62. Heeschen C, Jang JJ, Weis M, et al.  Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001;7:833–839
  63. Chalon S, Moreno H, Hoffman BB, et al.  Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers. Clin Pharmacol Ther. 1999;65:295–303
  64. Schlaifer JD, Mancini GB, O’Neill BJ, et al.  Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. TREND Investigators. Trial on Reversing Endothelial Dysfunction. Cardiovasc Drugs Ther. 1999;13:201–209
  65. Burke AP, Farb A, Malcom GT, et al.  Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276–1282
  66. Ichiki K, Ikeda H, Haramaki N, et al.  Long-term smoking impairs platelet-derived nitric oxide release. Circulation. 1996;94:3109–3114
  67. Newby DE, McLeod AL, Uren NG, et al.  Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking (direct link between endothelial dysfunction and atherothrombosis). Circulation. 2001;103:1936–1941
  68. Simpson AJ, Gray RS, Moore NR, et al.  The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol. 1997;97:208–213
  69. Zidovetzki R, Chen P, Fisher M, et al.  Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway. Stroke. 1999;30:651–655
  70. Matetzky S, Tani S, Kangavari S, et al.  Smoking increases tissue factor expression in atherosclerotic plaques (implications for plaque thrombogenicity). Circulation. 2000;102:602–604
  71. Blache D. Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol. 1995;268:H679–H685
  72. Nowak J, Murray JJ, Oates JA, et al.  Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation. 1987;76:6–14
  73. The NNDA t-PA Stroke Study Group . Intracerebral hemorrhage after intravenous t-PA therapy for schemic stroke. Stroke. 1997;28:2109–2118
  74. Jensen EJ, Pedersen B, Frederiksen R, et al.  prospective study on the effect of smoking and nicotine substitution on leucocyte blood counts and relation between blood leucocytes and lung function. Thorax. 1998;53:784–789
  75. Tracy RP, Psaty BM, Macy E, et al.  Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167–2176
  76. Tuut M, Hense H-W. Smoking, other risk factors and fibrinogen levels (Evidence of effect modification). Ann Epidemiol. 2001;11:232–238
  77. Lehr HA, Frei B, Arfors KE. Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc Natl Acad Sci U S A. 1994;91:7688–7692
  78. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  79. Lehr HA, Weyrich AS, Saetzler RK, et al.  Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest. 1997;99:2358–2364
  80. Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells (reversibility with oral L-arginine but not vitamin C). J Am Coll Cardiol. 1997;29:491–497
  81. Totti N, McCusker KT, Campbell EJ, et al.  Nicotine is chemotactic for neutrophils and enhances neutrophil responsiveness to chemotactic peptides. Science. 1984;223:169–173
  82. Yong T, Zheng MQ, Linthicum DS. Nicotine induces leukocyte rolling and adhesion in the cerebral microcirculation of the mouse. J Neuroimmunol. 1997;80:158–164
  83. Aicher A, Heeschen C, Mohaupt M, et al.  Nicotine strongly activates dendritic cell-mediated adaptive immunity (potential role for progression of atherosclerotic lesions). Circulation. 2003;107:604–611
  84. Benowitz NL, Fitzgerald GA, Wilson M, et al.  Nicotine effects on eicosanoid formation and hemostatic function (comparison of transdermal nicotine and cigarette smoking). J Am Coll Cardiol. 1993;22:1159–1167
  85. Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis. 2003;45:405–414
  86. Axelsson T, Jansson PA, Smith U, et al.  Nicotine infusion acutely impairs insulin sensitivity in type 2 diabetic patients but not in healthy subjects. J Intern Med. 2001;249:539–544
  87. Eliasson B, Taskinen MR, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation. 1996;94:878–881
  88. Assali AR, Beigel Y, Schreibman R, et al.  Weight gain and insulin resistance during nicotine replacement therapy. Clin Cardiol. 1999;22:357–360
  89. Arcaro G, Cretti A, Balzano S, et al.  Insulin causes endothelial dysfunction in humans (sites and mechanisms). Circulation. 2002;105:576–582
  90. Hirai N, Kawano H, Hirashima O, et al.  Insulin resistance and endothelial dysfunction in smokers (effects of vitamin C). Am J Physiol Heart Circ Physiol. 2000;279:H1172–H1178
  91. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations (An analysis of published data). Br Med J. 1989;298:784–788
  92. Hellerstein MK, Benowitz NL, Neese RA, et al.  Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J Clin Invest. 1994;93:265–272
  93. Stubbe I, Eskilsson J, Nilsson-Ehle P. High-density lipoprotein concentrations increase after stopping smoking. Br Med J. 1982;284:1511–1513
  94. Freeman DJ, Griffin BA, Murray E, et al.  Smoking and plasma lipoproteins in man (effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution). Eur J Clin Invest. 1993;23:630–640
  95. Harats D, Ben-Naim M, Dabach Y, et al.  Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis. 1989;79:245–252
  96. Stefanovich V, Gore I, Kajiyama G, et al.  The effect of nicotine on dietary atherogenesis in rabbits. Exp Molec Path. 1969;11:71–81
  97. Cluette-Brown J, Mulligan J, Doyle K, et al.  Oral nicotine induces an atherogenic lipoprotein profile. Proc Soc Exp Biol Med. 1986;182:409–413
  98. Quensel M, Agardh C-D, Nilsson-Ehle P. Nicotine does not affect plasma lipoprotein concentrations in healthy men. Scand J Clin Lab Invest. 1989;49:149–153
  99. Thomas GAO, Davies SV, Rhodes J, et al.  Is transdermal nicotine associated with cardiovascular risk?. J R Coll Physic Lond. 1995;29:392–396
  100. Allen SS, Hatsukami D, Gorsline J, et al.  Cholesterol changes in smoking cessation using the transdermal nicotine system. Prev Med. 1994;23:190–196
  101. Wang XL, Raveendran M, Wong J. Genetic influence on cigarette-induced cardiovascular disease. Prog Cardiovasc Dis. 2003;45:361–382
  102. Wang XL, Greco M, Sim AS, et al.  Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis. 2002;162:391–397
  103. Wang J, Dudley DK, Wang XL. Haplotype-specific effects on endothelial NO synthase promoter efficiency (modifiable by cigarette smoking). Arterioscler Thromb Vasc Biol. 2002;22:e1–e4
  104. Wang XL, Sim AS, Badenhop RF, et al.  A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med. 1996;2:41–45
  105. Wang XL, Wang J, Wilcken DE. Interactive effect of the p53 gene and cigarette smoking on coronary artery disease. Cardiovasc Res. 1997;35:250–255
  106. Humphries SE, Luong LA, Montgomery HE, et al.  Gene-environment interaction in the determination of levels of plasma fibrinogen. Thrombos Haemostas. 1999;82:818–825
  107. Barakat K, Kennon S, Hitman GA, et al.  Interaction between smoking and the glycoprotein IIIa P1(A2) polymorphism in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2001;38:1639–1643
  108. Holm J, Hillarp A, Zoller B, et al.  Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome. Thromb Haemost. 1999;81:857–860
  109. Li R, Boerwinkle E, Olshan AF, et al.  Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis. 2000;149:451–462
  110. Sen-Banerjee S, Siles X, Campos H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2120–2126
  111. Arinami T, Ohtsuki T, Yamakawa-Kobayashi K, et al.  A synergistic effect of serotonin transporter gene polymorphism and smoking in association with CHD. Thromb Haemost. 1999;81:853–856
  112. Holtzman JL, Weeks CE, Kvam DC, et al.  Identification of drug interactions by meta-analysis of premarketing trials (the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate). Clin Pharmacol Ther. 1989;46:1–8
  113. Walle T, Walle UK, Cowart TD, et al.  Selective induction of propranolol metabolism by smoking (additional effects on renal clearance of metabolites). J Pharmacol Exp Ther. 1987;241:928–933
  114. Jafri SM, Tilley BC, Peters R, et al.  Effects of cigarette smoking and propranolol in survivors of acute myocardial infarction. Am J Cardiol. 1990;65:271–276
  115. Thomson CC, Rigotti NA. Hospital and clinic-based smoking cessation interventions for smokers with cardiovascular disease. Prog Cardiovasc Dis. 2003;45:459–480
  116. Joseph AM, Fu S. Safety issues in pharmacology for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis. 2003;45:429–442
  117. Isles C, Brown JJ, Cumming AM, et al.  Excess smoking in malignant-phase hypertension. Br Med J. 1979;1:579–581
  118. Suskin N, Sheth T, Negassa A, et al.  Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;37:1677–1682
  119. Hwang SL, Waldholt M. Heart attacks reported in patch users still smoking. Wall Street Journal (B1). 1992;
  120. Zevin S, Jacob P, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther. 1998;64:87–95
  121. Murray RP, Bailey WC, Daniels K, et al.  Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Chest. 1996;109:438–445
  122. Mahmarian JJ, Moye LA, Nasser GA, et al.  Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol. 1997;30:125–130
  123. Lightwood J. Economics of smoking and cardiovascular disease. Prog Cardiovasc Dis. 2003;45:xx
  124. Brown AI, Garber AM. A concise review of the cost-effectiveness of coronary heart disease prevention. Med Clin North Am. 2000;84:279–297 xi

☆ Preparation of this manuscript supported in part by USPHS grants DA02277 and DA12393 from the National Institute on Drug Abuse and by the Flight Attendants Medical Research Institute.

PII: S0033-0620(03)00087-2

doi: 10.1016/S0033-0620(03)00087-2

Progress in Cardiovascular Diseases
Volume 46, Issue 1 , Pages 91-111 , July 2003

Article Tools

* Image Usage & Resolution